Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538983 | 0.79 | — | — | |
| SCHEMBL17971811 | 0.76 | — | — | |
| SCHEMBL15468843 | 0.73 | TOP2A (0.30) | — | |
| SCHEMBL2661926 | 0.72 | — | — | |
| SCHEMBL26804445 | 0.72 | — | — | |
| SCHEMBL25758466 | 0.70 | — | — | |
| SCHEMBL12702549 | 0.68 | GSK3A (0.33) | GSK3AGSK3BCCR6 | |
| SCHEMBL784155 | 0.67 | DHFR (0.35) | — | |
| SCHEMBL14640297 | 0.66 | APAF1 (0.35) | — | |
| SCHEMBL16639881 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-23 | — | — | US | disclosed |
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | ILLUMINA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12031178-B2 | Cyclooctatetraene containing dyes and compositions | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-09 | — | — | US | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230383342-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | ILLUMINA, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11827931-B2 | Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-11-28 | — | — | US | disclosed |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | ILLUMINA, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20230313292-A1 | CHROMENOQUINOLINE DYES AND USES IN SEQUENCING | ILLUMINA, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230314322-A1 | SYSTEMS AND METHODS OF SEQUENCING POLYNUCLEOTIDES | ILLUMINA, INC. | 2023-10-05 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043637-B2 | Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing | BLVRB, BCDIN3D, FOSB | GSK3A 4858/4885GSK3B 4609/4885CCR6 3656/4885 |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | GSK3A 2823/4885GSK3B 3611/4885CCR6 3561/4885 |
| US-20240240217-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' BLOCKING GROUPS AND CLEAVABLE LINKERS | NT5C2, DUT, NT5C3B | GSK3A 4178/4885GSK3B 3746/4885CCR6 3768/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | GSK3A 83/4885GSK3B 45/4885CCR6 572/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | GSK3A 2331/4885GSK3B 2177/4885CCR6 430/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | GSK3A 3457/4885GSK3B 3895/4885CCR6 1011/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | GSK3A 726/4885GSK3B 645/4885CCR6 1107/4885 |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | NT5C3B, NSUN2, DUT | GSK3A 2799/4885GSK3B 2213/4885CCR6 1566/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | GSK3A 3883/4885GSK3B 4069/4885CCR6 1219/4885 |
| US-11827931-B2 | Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group | PCNA, NOP2, POLRMT | GSK3A 3124/4885GSK3B 3074/4885CCR6 2113/4885 |
| US-11787831-B2 | Nucleosides and nucleotides with 3′ acetal blocking group | DUT, ADAR, NT5C3B | GSK3A 1721/4885GSK3B 1571/4885CCR6 509/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | GSK3A 3359/4885GSK3B 3850/4885CCR6 1773/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | GSK3A 3323/4885GSK3B 3815/4885CCR6 473/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | GSK3A 1512/4885GSK3B 1585/4885CCR6 1334/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | GSK3A 3439/4885GSK3B 3311/4885CCR6 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.